About BPC-157 Get
Editorial standards, sourcing methodology, and independence statement.
- [01]Understand who operates this site and what it is not.
- [02]Understand the sourcing methodology and citation standards used across all course modules.
- [03]Understand the disclaimer and regulatory context governing this site's content.
Who We Are
BPC-157 Get is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 (Body Protection Compound 157). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain modifier "Get" is editorial framing — a position this publisher occupies relative to the literature: get the research, get the record, get the course. It is not a claim about services offered. This site does not offer treatment, consultation, prescription services, or any form of commercial transaction. It is a research-literature course site.
No author or editor of this site is identified by name. The site does not employ or consult clinicians, pharmacologists, or researchers in the production of its content. All content is editorial commentary on publicly available peer-reviewed literature, organized and summarized for educational purposes.
Editorial Standards
Every quantitative claim on this site cites a peer-reviewed primary source. The references index on /references contains the full bibliography. Acceptable citation sources are: PubMed-indexed journals, PubMed Central, NIH, ClinicalTrials.gov, and peer-reviewed publisher sites (with DOI verification). Review articles and narrative reviews are used for framing and synthesis and are labeled accordingly. Editorial claims (identifying limitations, characterizing evidence weight, noting the concentration of research origin) are drawn from language in the primary and review sources themselves.
This site does not use: anecdote, self-report, forum discussion, or any non-peer-reviewed source as a basis for content claims. The distinction between rodent preclinical data, in vitro data, and human pilot data is explicitly maintained throughout every module.
Content is reviewed periodically for accuracy against new publications. The most recent primary literature cited on this site extends to 2026 (Yuan et al., International Journal of Molecular Sciences).
What This Site Is Not
This site is not a source of medical advice. None of the information presented here should be construed as a recommendation to use, purchase, administer, or consider BPC-157 or any related compound for any purpose.
BPC-157 is not approved by the FDA, EMA, or any other regulatory authority for human therapeutic use. It is classified by the World Anti-Doping Agency under the S0 Non-Approved Substances category and is prohibited for competitive athletes both in- and out-of-competition.
This site does not sell any product and is not affiliated with any vendor of BPC-157 or any related peptide. It does not accept advertising, affiliate revenue, or sponsorship from any commercial entity with a financial interest in BPC-157 or related compounds.
If you have questions about a specific medical condition, please consult a licensed healthcare provider. If you are a competitive athlete with questions about prohibited substances, please consult your national anti-doping organization.
Glossary
- Angiogenesis
- The formation of new blood vessels from pre-existing vasculature. A critical component of wound healing and tissue repair that BPC-157 modulates in a tissue-context-dependent manner.
- Cytoprotection
- The ability of a substance to protect individual cells from injury or death. BPC-157 was originally characterized by its cytoprotective effects on gastric mucosa — helping cells in the stomach lining withstand damage from experimental ulcerogens.
- VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)
- A cell-surface receptor that, when activated, drives the growth and migration of endothelial cells to form new blood vessels. BPC-157 upregulates VEGFR2 expression in healing tissues.
- Akt-eNOS axis
- A signaling pathway in which the kinase Akt phosphorylates endothelial nitric oxide synthase (eNOS), stimulating nitric oxide production. Nitric oxide causes blood vessel dilation and promotes angiogenesis and cell survival.
- Pentadecapeptide
- A peptide composed of exactly 15 amino acids. BPC-157 is classified as a pentadecapeptide because its active sequence (GEPPPGKPADDAGLV) contains 15 amino acid residues.
- Ischemia-Reperfusion Injury
- Tissue damage that occurs when blood supply is restored to an organ after a period of oxygen deprivation. The return of oxygenated blood paradoxically triggers inflammatory and oxidative damage. BPC-157 has been studied as a protective agent in these models.
- FAK-Paxillin Pathway
- Focal Adhesion Kinase (FAK) and its binding partner paxillin form a signaling complex that mediates cell migration, adhesion, and fibroblast proliferation. BPC-157 activates this pathway, contributing to enhanced collagen synthesis.
- Myotendinous Junction
- The anatomical interface where muscle fibers connect to tendon. A specific focus of BPC-157 research examining how the peptide facilitates muscle-to-bone and muscle-to-tendon healing.
- Nitric Oxide (NO) System
- A network of enzymes (including eNOS, iNOS, nNOS) that produce nitric oxide, a gaseous signaling molecule regulating vascular tone, inflammation, and neuronal function. BPC-157 modulates NO production contextually.
- WADA S0 Prohibited Substance
- The World Anti-Doping Agency's S0 category covers pharmacological substances not approved by any regulatory authority for human therapeutic use. BPC-157 is classified here, making it prohibited for competitive athletes subject to the World Anti-Doping Code.